摘要
目的:建立阿折地平血药浓度的液相色谱-质谱(LC-MS)测定法,进行人体药动学研究。方法:采用LC-MS法,测定16名健康受试者口服受试制剂(单剂量含阿折地平8,16 mg和多剂量)后血浆中阿折地平浓度。结果:口服受试制剂(单剂量8,16 mg)后,估算的阿折地平的药动学参数分别为:t_(1/2β)为(22.8±s 2.4),(24±4)h;t_(max)为(2.8±1.2),(3.0±0.9)h;c_(max)为(8.7±1.2),(19±4)μg·L^(-1);V_d为(1749±964),(2480±2212)L;AUC_(0~96)为(186±47),(429±145)μg·h·L^(-1);MRT为(25.7±1.3),(26.2±2.2)h。多剂量口服受试制剂(8mg,qd×7 d)血药浓度达稳态后估算的阿折地平的药动学参数c_(ss max)为(15.0±2.3)μg·L^(-1),t_(max)为(2.4±0.9)h,c_(ss min)为(3.8±0.9)μg·L^(-1),c_(av)为(7.0±1.5)μg·L^(-1),DF为(1.6±0.3),AUC_(ss)为(169±37)μg·h·L^(-1)。结论:本方法结果准确,灵敏度高,阿折地平在大部分人体内的过程符合二室开放模型,其主要药动学参数与国外文献报道数据一致,可为临床给药方案提供参考。
AIM: To establish a LC-MS method to study the pharmacokinetics of azelnidipine tablet in 16 Chinese healthy volunteers. METHODS: Sixteen healthy volunteers received tested tablet for each of a single oral dose of azelnidipine 8, 16 mg and muhidose. Drug concentrations in plasma were determined by LC-MS. RESULTS: The main pharmacokinetic parameters of single oral doses (8 mg, 16 mg) were as follow: t+β(22.8 ± s 2.4), (24 ± 44) h; tmax(2.8 ± 1.2), (3.0 ± 0.9) h; cmax (8.7 ± 1.2), (19 ± 4) μg·L^-1; Vd (1 749±964), (2480±2212) L; AUC0-96 (186±47), (429± 145)μg·L^-1; MRT (25.7 ± 1.3), (26.2± 2.2) h. The main pharmacokinetic parameters of multidose were as follow: css max (15.0 ± 2.3) μg·L^-1; tmax= (2.4 ± 0.9) h; css max (3.8±0.9)μg·L^-1, cSN (7.0± 1.5) μg·L^-1; DF (1.6±0.3); AUC, (169±37) μg·L^-1. CONCLUSION: The method is accurate, sensitive and reliable, coincided with a two-compartment open pharmcokinetics model for azelnidipine plasma concentration-time data analysis. The main pharmacokinetic parameters of the domestic azelnidipine tablet were similar to those reported abroad, providing information for clinical application.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2007年第1期36-39,共4页
Chinese Journal of New Drugs and Clinical Remedies
关键词
阿折地平
药动学
色谱法
高压液相
光谱法
质量
电喷雾电离
azelnidipine
pharmacokinetics
chromatography, high pressure liquid
spectrometry, mass, electrospray ionization